Antibodies-based immunotherapy in multiple myeloma
Antibody-based immunotherapy is now established as a key therapeutic modality for multiple myeloma. Owing to the ability of these antibodies to selectively target myeloma or both myeloma and T cells, changes in myeloma and T cells over time are a major exploratory endpoints for this class of therapeutics.
Our research is evaluating possible mechanisms of resistance to antibody-based immunotherapy in myeloma patients entering clinical trials as related to the phenotype and function of T cells.
This research will inform future development and clinical application of antibody-based immunotherapy and move us closer to a cure in myeloma.
